CytomX Therapeutics, Inc. (CTMX) Spending and interest coverage
- R&D / revenue · 12 months: Value 400.89%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 55.43%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 400.89% | Research and development expense / revenue. Period ending 2026-06-30. $73.38M ÷ $18.30M × 100 ≈ 400.89% |
| Stock-based compensation / revenue · 12 months | 55.43% | Share-based compensation / revenue. Period ending 2026-06-30. $10.15M ÷ $18.30M × 100 ≈ 55.43% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 73.38M USD | Research and Development Expense |
| Revenue | 18.30M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 10.15M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -87.15M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $73.38M | $18.30M | $10.15M | $-87.15M | (m) | 400.89% | 55.43% | (m) | (m) |
| 2026-03-31 | $69.10M | $35.54M | $9.00M | $-64.66M | (m) | 194.41% | 25.32% | (m) | (m) |
| 2025-12-31 | $68.73M | $76.20M | $6.30M | $-22.36M | (m) | 90.19% | 8.27% | (m) | (m) |
| 2025-09-30 | $62.28M | $113.63M | $6.71M | $23.25M | (m) | 54.81% | 5.90% | (m) | (m) |
| 2025-06-30 | $68.35M | $141.10M | $7.32M | $43.13M | (m) | 48.44% | 5.19% | (m) | (m) |
| 2025-03-31 | $80.20M | $147.56M | $7.77M | $35.96M | (m) | 54.35% | 5.27% | (m) | (m) |
| 2024-12-31 | $83.38M | $138.10M | $7.67M | $25.00M | (m) | 60.38% | 5.55% | (m) | (m) |
| 2024-09-30 | $87.98M | $126.62M | $8.34M | $6.71M | (m) | 69.48% | 6.58% | (m) | (m) |
| 2024-06-30 | $83.06M | $119.57M | $7.57M | $5.72M | (m) | 69.46% | 6.33% | (m) | (m) |
| 2024-03-31 | $78.56M | $119.18M | $8.06M | $10.83M | (m) | 65.92% | 6.76% | (m) | (m) |
| 2023-12-31 | $77.68M | $101.21M | $8.56M | $-6.48M | (m) | 76.75% | 8.46% | (m) | (m) |
| 2023-09-30 | $77.86M | $94.73M | $8.58M | $-15.39M | (m) | 82.19% | 9.05% | (m) | (m) |
| 2023-06-30 | $91.78M | $79.49M | $10.04M | $-48.22M | (m) | 115.45% | 12.64% | (m) | (m) |
| 2023-03-31 | $102.27M | $67.62M | $12.16M | $-74.93M | (m) | 151.23% | 17.99% | (m) | (m) |
| 2022-12-31 | $111.65M | $53.16M | $13.13M | $-101.33M | (m) | 210.01% | 24.69% | (m) | (m) |
| 2022-09-30 | $128.66M | $71.94M | $14.10M | $-98.96M | (m) | 178.84% | 19.60% | (m) | (m) |
| 2022-07-13 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $127.44M | $72.62M | $14.57M | $-97.66M | (m) | 175.50% | 20.06% | (m) | (m) |
| 2022-03-31 | $122.38M | $70.74M | $13.50M | $-92.12M | (m) | 173.01% | 19.09% | (m) | (m) |
| 2021-12-31 | $114.19M | $69.57M | $13.17M | $-83.78M | (m) | 164.14% | 18.93% | (m) | (m) |
| 2021-09-30 | $99.62M | $66.22M | $13.04M | $-72.25M | (m) | 150.44% | 19.70% | (m) | (m) |
| 2021-06-30 | $94.53M | $66.42M | $13.72M | $-64.51M | (m) | 142.32% | 20.65% | (m) | (m) |
| 2021-03-31 | $92.49M | $66.74M | $13.81M | $-61.44M | (m) | 138.59% | 20.69% | (m) | (m) |
| 2020-12-31 | $112.94M | $100.36M | $14.79M | $-48.60M | (m) | 112.53% | 14.73% | (m) | (m) |
| 2020-09-30 | $127.37M | $92.27M | $15.48M | $-71.20M | (m) | 138.04% | 16.78% | (m) | (m) |
| 2020-06-30 | $131.29M | $85.19M | $15.98M | $-82.03M | (m) | 154.11% | 18.76% | (m) | (m) |
| 2020-03-31 | $138.06M | $77.60M | $17.92M | $-97.12M | (m) | 177.92% | 23.09% | (m) | (m) |
| 2019-12-31 | $131.62M | $57.49M | $19.10M | $-110.89M | (m) | 228.95% | 33.22% | (m) | (m) |
| 2019-09-30 | $123.48M | $60.68M | $19.61M | $-99.33M | (m) | 203.50% | 32.31% | (m) | (m) |
| 2019-06-30 | $123.07M | $62.48M | $19.68M | $-96.78M | (m) | 196.97% | 31.49% | (m) | (m) |
| 2019-03-31 | $117.78M | $74.80M | $18.38M | $-78.81M | (m) | 157.46% | 24.57% | (m) | (m) |
| 2018-12-31 | $103.87M | $59.50M | $16.88M | $-77.87M | (m) | 174.56% | 28.37% | (m) | (m) |
| 2018-09-30 | $96.26M | $75.10M | $15.01M | $-53.31M | (m) | 128.17% | 19.99% | (m) | (m) |
| 2018-06-30 | $97.64M | $86.74M | $13.38M | $-41.16M | (m) | 112.56% | 15.42% | (m) | (m) |
| 2018-03-31 | $100.16M | $74.15M | $12.23M | $-53.27M | (m) | 135.07% | 16.49% | (m) | (m) |
| 2017-12-31 | $92.28M | $71.62M | $11.29M | $-46.26M | (m) | 128.84% | 15.76% | (m) | (m) |
| 2017-09-30 | $86.92M | $50.82M | $11.16M | $-59.24M | (m) | 171.03% | 21.96% | (m) | (m) |
| 2017-06-30 | $71.34M | $30.13M | $11.10M | $-63.13M | (m) | 236.76% | 36.84% | (m) | (m) |
| 2017-03-31 | $55.97M | $24.47M | $10.48M | $-52.02M | $1.54M | 228.68% | 42.82% | -33.73× | Reported |
| 2016-12-31 | $54.76M | $15.04M | $10.10M | $-59.59M | $1.69M | 363.99% | 67.11% | -35.28× | Reported |
| 2016-09-30 | $48.91M | $10.76M | $9.39M | $-56.88M | $1.68M | 454.60% | 87.31% | -33.94× | Reported |
| 2016-06-30 | $44.73M | $9.24M | $8.02M | $-53.23M | $1.91M | 483.88% | 86.74% | -27.84× | Reported |
| 2016-03-31 | $37.06M | $8.19M | $6.17M | $-44.52M | $1.85M | 452.31% | 75.34% | -24.00× | Reported |
| 2015-12-31 | $28.36M | $7.71M | $3.99M | $-33.20M | $1.73M | 367.70% | 51.69% | -19.17× | Reported |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $7.56M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $6.18M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $28.30M | $5.08M | $553.00K | $-29.77M | $487.00K | 557.46% | 10.89% | -61.12× | Reported |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $10.89M | $888.00K | $343.00K | $-14.96M | $254.00K | 1226.35% | 38.63% | -58.88× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |